271. 強直性脊椎炎 ［臨床試験数：531，薬物数：343（DrugBank：66），標的遺伝子数：41，標的パスウェイ数：141］
Searched query = "Ankylosing spondylitis", "Spondylarthritis ankylopoietica"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.
|1||NCT00558506||January 2008||14/11/2007||Pilot Open Label Clinical Trial With Abatacept in Ankylosing Spondylitis||Pilot Open Label Clinical Trial With Abatacept in Ankylosing Spondylitis||Ankylosing Spondylitis||Drug: abatacept||Charite University, Berlin, Germany||Bristol-Myers Squibb||Recruiting||18 Years||65 Years||Both||30||Phase 2||Germany|
|2||EUCTR2007-002967-28-DE||19/10/2007||24/08/2007||Pilot open label clinical trial with Abatacept in Ankylosing Spondylitis - ABATACEPT-AS-01||Pilot open label clinical trial with Abatacept in Ankylosing Spondylitis - ABATACEPT-AS-01||T cell responses have been demonstrated against proteoglycan (an important cartilage protein) in human arthritides including ankylosing spondylitis. We suggest that a chronic, probably T cell mediated, immune response against cartilage is relevant in the pathogenesis of AS.Based on the above described findings about the role of T-cells in ankylosing spondylitis we assume that Abatacept has the potential to be an effective drug for treating ankylosing spondylitis.||Trade Name: not applicable|
Product Name: Orencia
Product Code: BMS-188667
INN or Proposed INN: Abatacept
Other descriptive name: CTLA4Ig
|Charité University Medicine||NULL||Not Recruiting||Female: yes|